Biomarin Pharmaceutical Inc. logo

Biomarin Pharmaceutical Inc. (BMRN)

Market Closed
1 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
64. 84
-0.39
-0.5979%
$
12.5B Market Cap
126.18 P/E Ratio
- Div Yield
1.78M Volume
1 Eps
$ 65.23
Previous Close
Add Transaction
Day Range
64.49 66.01
Year Range
49.26 70.98
Want to track BMRN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

Based on the late-stage data, BioMarin plans to submit a regulatory filing for expanding the label of its PKU drug Palynziq in adolescents before this year's end.

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?

BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue?

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

BMRN vs. CSLLY: Which Stock Should Value Investors Buy Now?

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive to value investors?

Zacks | 1 year ago
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

Scoop Up These 4 Stocks With Amazing Interest Coverage Ratio

BOOT, STRL, DECK & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

Zacks | 1 year ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
BMRN or CSLLY: Which Is the Better Value Stock Right Now?

BMRN or CSLLY: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 1 year ago
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 1 year ago
BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why

BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why

BioMarin (BMRN) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 1 year ago
Loading...
Load More